Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Hold” by Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $52.00.

Several research analysts have recently issued reports on the company. Craig Hallum raised their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Benchmark reiterated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, Barclays lifted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st.

Omnicell Stock Performance

NASDAQ:OMCL opened at $47.14 on Wednesday. The stock’s fifty day moving average price is $44.97 and its two-hundred day moving average price is $38.69. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -120.87, a P/E/G ratio of 34.95 and a beta of 0.78.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of the company. Arizona State Retirement System raised its stake in shares of Omnicell by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after purchasing an additional 357 shares during the period. Diversified Trust Co increased its position in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after acquiring an additional 494 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares during the last quarter. Finally, Curi RMB Capital LLC increased its position in shares of Omnicell by 0.7% in the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock valued at $3,872,000 after acquiring an additional 651 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.